Beta Bionics, Inc.
BBNX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|
| Revenue | $65 | $12 | $0 |
| % Growth | 442.9% | 6,601.1% | – |
| Cost of Goods Sold | $29 | $6 | $0 |
| Gross Profit | $36 | $6 | $0 |
| % Margin | 55.1% | 52.6% | 100% |
| R&D Expenses | $26 | $18 | $31 |
| G&A Expenses | $18 | $12 | $25 |
| SG&A Expenses | $55 | $24 | $33 |
| Sales & Mktg Exp. | $37 | $12 | $9 |
| Other Operating Expenses | $0 | $0 | $1 |
| Operating Expenses | $81 | $42 | $66 |
| Operating Income | -$45 | -$36 | -$66 |
| % Margin | -69.5% | -298.9% | -36,784.4% |
| Other Income/Exp. Net | -$10 | -$8 | $1 |
| Pre-Tax Income | -$55 | -$44 | -$65 |
| Tax Expense | $0 | $0 | $0 |
| Net Income | -$55 | -$44 | -$65 |
| % Margin | -84.1% | -367.6% | -36,173.7% |
| EPS | -8.6 | -8.31 | -12.96 |
| % Growth | -3.5% | 35.9% | – |
| EPS Diluted | -8.6 | -8.31 | -12.96 |
| Weighted Avg Shares Out | 6 | 5 | 5 |
| Weighted Avg Shares Out Dil | 6 | 5 | 5 |
| Supplemental Information | – | – | – |
| Interest Income | $4 | $2 | $0 |
| Interest Expense | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 |
| EBITDA | -$44 | -$35 | -$63 |
| % Margin | -67.7% | -288.7% | -35,418.4% |